AstraZeneca Accepts Proposal for Combination Vaccination with Russian Vaccine 'Sputnik V'

COVID-19 vaccine developed by AstraZeneca
[Image source=Yonhap News]

[Asia Economy Reporter Son Sun-hee] AstraZeneca, a multinational pharmaceutical company headquartered in the UK, will begin trials of a combined vaccination with the Russian-made novel coronavirus (COVID-19) vaccine 'Sputnik V' starting at the end of the year.

According to major foreign media on the 11th (local time), AstraZeneca is reported to have accepted a proposal for combined vaccination to enhance vaccine efficacy from the Russian Direct Investment Fund (RDIF), which supported the development of Sputnik V.

AstraZeneca issued a statement on the same day, saying, "We are considering ways to evaluate various vaccine combinations and will soon begin joint research with the institution that developed Sputnik V." Sputnik V is a COVID-19 vaccine developed by the Gamaleya National Research Center of Epidemiology and Microbiology under the Russian Ministry of Health and was approved by the Russian government last August.

The COVID-19 vaccine that AstraZeneca is developing together with the University of Oxford in the UK was once considered to be leading the development race, but it is known that trials were halted in September after participants in the vaccine clinical trial experienced unexplained side effects.

This content was produced with the assistance of AI translation services.